Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase No.11. International Agency for Research on Cancer, Lyon

Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A (2009) V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 35:707–713

Forgac M (2007) Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat Rev Mol Cell Biol 8:917–929

Sasse F, Steinmetz H, Hofle G, Reichenbach H (2003) Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 56:520–525

Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H et al (2005) Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem 6:13

Bockelmann S, Menche D, Rudolph S, Bender T, Grond S et al (2010) Archazolid A binds to the equatorial region of the c-ring of the vacuolar H+−ATPase. J Biol Chem 285:38304–38314

von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H et al (2013) Mode of cell death induction by pharmacological vacuolar H+−ATPase (V-ATPase) inhibition. J Biol Chem 288:1385–1396

Kerbel RS, Kobayashi H, Graham CH (1994) Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56:37–47

Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627

Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

Efferth T (2001) The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1:45–65

Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237–262

Ferry DR, Kerr DJ (1994) Multidrug resistance in cancer. BMJ 308:148–149

Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398

Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967

Ferreira CG, Tolis C, Giaccone G (1999) p53 and chemosensitivity. Ann Oncol 10:1011–1021

Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J et al (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3:192–222

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284

Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R et al (1990) Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50:6793–6799

Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y et al (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665–15670

Kawanobe T, Kogure S, Nakamura S, Sato M, Katayama K et al (2012) Expression of human ABCB5 confers resistance to taxanes and anthracyclines. Biochem Biophys Res Commun 418:736–741

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S et al (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S et al (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827–4833

Tajima Y, Nakagawa H, Tamura A, Kadioglu O, Satake K, et al (2013) Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine

Zhao Q, Zeino M, Eichhorn T, Herrmann J, Müller R et al (2013) Molecular docking studies of myxobacterial disorazoles and tubulysins to tubulin. J Biosci Med 3:31–43

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791

Ferreira RJ, Ferreira MJ, dos Santos DJ (2013) Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 53:1747–1760

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972

Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:1587–1595

Min YS, Yi EH, Lee JK, Choi JW, Sim JH et al (2012) CK20 expression enhances the invasiveness of tamoxifen-resistant MCF-7 cells. Anticancer Res 32:1221–1228

Webb BA, Chimenti M, Jacobson MP, Barber DL (2011) Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 11:671–677

Fais S, De Milito A, You H, Qin W (2007) Targeting vacuolar H+−ATPases as a new strategy against cancer. Cancer Res 67:10627–10630

Nishi T, Forgac M (2002) The vacuolar (H+)-ATPases–nature’s most versatile proton pumps. Nat Rev Mol Cell Biol 3:94–103

Lu X, Qin W (2012) Vacuolar H(+)-ATPase in cancer cells: structure and function. Atl Genet Cytogenet Oncol Haematol 16:252–259

Zhan H, Yokoyama K, Otani H, Tanigaki K, Shirota N et al (2003) Different roles of proteolipids and 70-kDa subunits of V-ATPase in growth and death of cultured human cells. Genes Cells 8:501–513

Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW et al (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639

Higgins CF, Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17:18–21

Sharom FJ (1997) The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160:161–175

Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S et al (2001) Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93:869–874

Ouar Z, Bens M, Vignes C, Paulais M, Pringel C et al (2003) Inhibitors of vacuolar H+−ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 370:185–193

Ma L, Center MS (1992) The gene encoding vacuolar H(+)-ATPase subunit C is overexpressed in multidrug-resistant HL60 cells. Biochem Biophys Res Commun 182:675–681

Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233–240

Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD et al (2001) P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61:1508–1516

Yu JL, Coomber BL, Kerbel RS (2002) A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70:599–609

Kuete V, Tchakam PD, Wiench B, Ngameni B, Wabo HK et al (2013) Cytotoxicity and modes of action of four naturally occuring benzophenones: 2,2′,5,6′-tetrahydroxybenzophenone, guttiferone E, isogarcinol and isoxanthochymol. Phytomedicine 20:528–536

Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R et al (2012) The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res 72:5976–5987

Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464